QStat Cartridge in Obstetric Patients

Status Enrolling by invitation

Clinical Trial Summary

This study will assess the performance of the Quantra System with the QStat Cartridge versus standard of care coagulation testing in pregnant women at risk of bleeding at delivery.

Clinical Trial Description

The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QStat Cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. These patients include the tobstetric hemorrhage population. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding five parameters that depict the functional status of a patient's coagulation system. This multicenter, prospective, observational pilot study will evaluate the performance of the Quantra System with the QStat Cartridge as compared to standard of care coagulation testing in pregnant women at risk of bleeding at delivery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06255496
Study type	Observational
Source	HemoSonics LLC
Contact
Status	Enrolling by invitation
Phase
Start date	May 9, 2024
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03680339` - The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS	Phase 4
Completed	`NCT03693599` - Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean	Phase 4
Completed	`NCT03707132` - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Recruiting	`NCT02306733` - Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally	Phase 3
Completed	`NCT01866241` - Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage	Phase 3
Not yet recruiting	`NCT01236482` - Oxytocin in Cesarean Delivery	Phase 4
Completed	`NCT03784794` - Patient Blood Management for Massive Obstetric Hemorrhage	N/A
Recruiting	`NCT04401839` - Amr Maneuver for Prevention of Postpartum Hemorrhage	N/A
Recruiting	`NCT06219538` - DAISY Uterine Drain Device Evaluation	N/A
Not yet recruiting	`NCT06333340` - Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery	N/A
Completed	`NCT01863706` - Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage	Phase 1
Completed	`NCT04723979` - NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
Terminated	`NCT04277962` - Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial	N/A
Completed	`NCT03570723` - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa	N/A
Completed	`NCT03117647` - Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage	N/A
Active, not recruiting	`NCT03069859` - Use of TXA to Prevent Postpartum Hemorrhage	Phase 2
Not yet recruiting	`NCT03891082` - A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section	N/A
Not yet recruiting	`NCT03463070` - Misoprostol Before and After Cesarean Section	Phase 3
Recruiting	`NCT05532215` - Sublingual Misoprostol in Reduction of Caesarean Blood Loss	N/A
Completed	`NCT03907605` - Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)